Detalles de la búsqueda
1.
Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).
Pituitary
; 25(6): 959-970, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36219274
2.
Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study.
Pituitary
; 24(6): 887-903, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34275099
3.
Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study.
Pituitary
; 23(3): 203-211, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31875276
4.
Pharmacokinetics and pharmacodynamics of a pasireotide subcutaneous depot (CAM4071) and comparison with immediate and long-acting release pasireotide.
Endocrine
; 84(3): 1125-1134, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38421556
5.
Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study.
Front Endocrinol (Lausanne)
; 15: 1250822, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38577574
6.
Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.
Front Endocrinol (Lausanne)
; 14: 1165681, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37876540
7.
Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.
Front Endocrinol (Lausanne)
; 14: 1236465, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37680892
8.
Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteers.
Endocrine
; 75(2): 537-548, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34741720
9.
Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.
Eur J Endocrinol
; 187(4): 531-541, 2022 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35980235
10.
Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.
J Clin Endocrinol Metab
; 107(7): e2882-e2895, 2022 06 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35325149
11.
Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
Neuroendocrinology
; 92 Suppl 1: 120-4, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20829632
12.
Risk factors and management of pasireotide-associated hyperglycemia in acromegaly.
Endocr Connect
; 9(12): 1178-1190, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33434154
13.
Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study.
Eur J Endocrinol
; 182(6): 583, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32217809
14.
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Lancet Diabetes Endocrinol
; 8(9): 748-761, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32730798
15.
Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma.
ESMO Open
; 3(5): e000388, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30094073
16.
Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.
Endocrine
; 53(1): 210-9, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26906713
17.
Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.
Endocrine
; 54(2): 516-523, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27209465
18.
Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?
J Clin Endocrinol Metab
; 88(7): 3090-8, 2003 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-12843148
19.
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Lancet Diabetes Endocrinol
; 2(11): 875-84, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25260838
Resultados
1 -
19
de 19
1
Próxima >
>>